Table 2.
Characteristics of the study population.
| Screened population (n = 117) | Study population (n = 52) | |
|---|---|---|
| Clinical characteristics | ||
| Age (years) | 54.1 ± 9.6 | 55.7 ± 4.8 |
| Male sex, no. (%) | 73 (62.4) | 23 (44.2) |
| BMI (Kg/m2) | 26.3 ± 3.8 | 25.8 ± 4.0 |
| Hypertension, no. (%) | 21 (17.9) | 7 (13.5) |
| Family history of CVD, no. (%) | 13 (11.1) | 7 (13.5) |
| Current smoker, no. (%) | 16 (13.7) | 9 (17.3) |
| Previous smoker, no. (%) | 41 (35.0) | 16 (30.8) |
| Physical inactivity, no. (%) | 31 (26.5) | 14 (26.9) |
| Systolic BP (mmHg) | 122 (115–130) | 125 (120–130) |
| Diastolic BP (mmHg) | 75 (68–80) | 80 (70–80) |
| Heart rate (bpm) | 66.1 ± 10.2 | 64.5 ± 9.7 |
| Waist circumference (cm) | 93.8 ± 12.2 | 92.2 ± 11.9 |
| WHR | 0.90 (0.87–0.96) | 0.86 (0.83–0.92) |
| Metabolic syndrome, no. (%) | 37 (31.6) | 16 (30.8) |
| Laboratory data | ||
| Total cholesterol (mg/dl) | 207.2 ± 32.2 | 246.2 ± 27.1 |
| HDL (mg/dl) | 57.0 ± 13.3 | 59.3 ± 13.6 |
| Triglycerides (mg/dl) | 95.0 (70.0–131.0) | 101.0 (75.5–163.5) |
| LDL (mg/dl) | 128.9 ± 27.5 | 164.0 ± 26.1 |
| Creatinine clearance (ml/min) | 90.0 (79.7–102.7) | 90.9 (75.6–100.4) |
| Creatinine (mg/dl) | 0.89 ± 0.13 | 0.84 ± 0.19 |
| 10-year cardiovascular risk | ||
| SCORE | ||
| <1%, no. (%) | 26 (22.2) | 9 (17.3) |
| 1–5%, no. (%) | 80 (68.4) | 43 (82.7) |
| Relative risk | ||
| 1 no. (%) | 68 (58.1) | 14 (26.9) |
| 2 no. (%) | 38 (32.5) | 23 (44.2) |
| >2 no. (%) | 10 (8.5) | 15 (28.9) |
| Cardiovascular therapy | ||
| Aspirin, no. (%) | 3 (2.6) | 4 (7.7) |
| ACEi/ARB, no. (%) | 19 (16.2) | 6 (11.5) |
| Beta-blocker, no. (%) | 1 (0.9) | 1 (1.9) |
| Other antihypertensive drugs, no. (%) | 9 (7.7) | 3 (5.8) |
The variables normally distributed are presented as mean ± SD, otherwise as median (IQR). BMI, body mass index; CVD, cardiovascular disease; BP, blood pressure; WHR, waist-hip ratio; HDL, high density lipoprotein; LDL, low density lipoprotein; SCORE, systemic coronary risk estimation; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker.